Interstitial Lung Disease Associated with Trastuzumab Deruxtecan in HER2D Metastatic Breast Cancer: a Real-world Experience

被引：0
|
作者：
Shaheen, A. [1 ]
Hayhurst, H. [1 ]
Omokhodion, O. [1 ]
Ayyad, A. [1 ]
机构：
[1] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 04期
关键词：
EMTANSINE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E111 / E112
页数：2
相关论文
共 50 条
  • [21] Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer
    Mougalian, S. S.
    Copher, R.
    McAllister, L.
    Radtchenko, J.
    Wang, E. C.
    Broscious, M.
    Yu, H-T
    Kish, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] Single institute experience of treatment for metastatic HER2 positive breast cancer patients with trastuzumab deruxtecan
    Kojima, Yasuyuki
    Tsugawa, Koichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S338 - S338
  • [23] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [24] New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2+
    Minot-This, Marie-Sophie
    Bellesoeur, Audrey
    BULLETIN DU CANCER, 2021, 108 (09) : 783 - 784
  • [25] Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan.
    Kish, Jonathan K.
    Mehta, Sandhya
    Kwong, Jackie
    Lam, Clara
    Falkenstein, Angelica
    Brown-Bickerstaff, Cherrishe
    Xiao, Dong
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [27] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [28] Trastuzumab deruxtecan for HER2+advanced breast cancer
    Lee, Jiyun
    Park, Yeon Hee
    FUTURE ONCOLOGY, 2021, 18 (01) : 7 - 19
  • [29] Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
    Jeanna Wallenta Law
    Alicyn Campbell
    Colin Weller
    Colden Johanson
    Ronda Broome
    Elisabeth Piault
    Monika Izano
    Andrew Schrag
    Mary Tran
    Thomas D. Brown
    Henry G. Kaplan
    Breast Cancer Research and Treatment, 2022, 196 : 603 - 611
  • [30] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
12345